Wave Life Sciences Ltd Reports Results For The Quarter Ended June 30: Earnings Summary

Wave Life Sciences

30/07/2026 18:38

WAVE Life Sciences Ltd WVE.OQ reported a quarterly adjusted loss of 34 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -31 cents.  The mean expectation of sixteen analysts for the quarter was for a loss of 31 cents per share. Wall Street expected results to range from -37 cents to -25 cents per share.
Revenue fell 73.9% to $2.27 million from a year ago; analysts expected $7.05 million. 
WAVE Life Sciences Ltd's reported EPS for the quarter was a loss of 34 cents​.
The company reported a quarterly loss of $69.36 million.
WAVE Life Sciences Ltd shares had held steady so far this quarter and lost 65.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 1.7% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for WAVE Life Sciences Ltd is $21.00, about 72.3% above its last closing price of $5.81
This summary was machine generated from LSEG data July 30 at 05:38 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.31
-0.34
Missed
Mar. 31 2026 
-0.33
-0.13
Beat
Dec. 31 2025 
-0.27
-0.30
Missed
Sep. 30 2025 
-0.30
-0.32
Missed